Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Keratosis, Actinic 29Uterine Cervical Dysplasia 14Carcinoma, Basal Cell 12Melanoma 10Glioma 6Glioblastoma 6Breast Neoplasms 5Uterine Cervical Neoplasms 4Neoplasm Metastasis 4Keratosis 4Condylomata Acuminata 4Precancerous Conditions 3Papillomavirus Infections 3Hutchinson's Melanotic Freckle 3Vulvar Neoplasms 2Urinary Bladder Neoplasms 2Squamous Intraepithelial Lesions 2Non-Muscle Invasive Bladder Neoplasms 2Neoplasms 2Hemangioma, Capillary 2HIV Infections 2Ependymoma 2Colorectal Neoplasms 2Brain Neoplasms 2Astrocytoma 2Warts 1Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) 1Virus Diseases 1Vaginal Neoplasms 1Stomach Neoplasms 1

Interventions

Restraint, Physical 2Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 2Human Papillomavirus DNA Tests 2Folic Acid 2Colposcopy 2epigallocatechin gallate 1Zinc Sulfate 1Vitamin B 12 1Vaginal Smears 1Papanicolaou Test 1Mindfulness-Based Stress Reduction 1Imiquimod 1High-Throughput Screening Assays 1Gelatin 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Atypical Squamous Cells of the Cervix × Imiquimod × Clear all
NCT02689726 2016-12-02

Safety, Tolerability, and Immunogenicity of GTL001 Vaccine Adjuvanted With Imiquimod Cream in HPV 16- and/or HPV 18-Infected Women Aged 25 to 65 Years, With Normal Cytology, ASCUS, or LSIL

Genticel

Phase 1 Terminated
13 enrolled

Atypical Squamous Cells of the Cervix

Data powered by HemOnc (CC BY 4.0) Colophon âš¡